Aichi Cancer Center Research Institute


Forschungseinrichtung

Standort der Organisation:
Nagoya, Japan


Publikationen in Kooperation mit FAU-Wissenschaftern


Go to first page Go to previous page 1 von 2 Go to next page Go to last page
Buckley, M.A., Woods, N.T., Tyrer, J.P., Mendoza-Fandino, G., Lawrenson, K., Hazelett, D.J.,... Freedman, M.L. (2019). Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-17-3864
Yang, Y., Wu, L., Shu, X., Lu, Y., Shu, X.-O., Cai, Q.,... Long, J. (2019). Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 79(3). https://dx.doi.org/10.1158/0008-5472.CAN-18-2726
Yao, J.C., Strosberg, J., Fazio, N., Pavel, M.E., Ruszniewski, P., Bergsland, E.,... Singh, S. (2018). Activity & safety of spartalizumab (PDR001) in patients (pts) with advanced neuroendocrine tumors (NET) of pancreatic (Pan), gastrointestinal (GI), or thoracic (T) origin, & gastroenteropancreatic neuroendocrine carcinoma (GEP NEC) who have progressed on prior treatment (Tx). In ANNALS OF ONCOLOGY. Munich, DE: OXFORD: OXFORD UNIV PRESS.
Earp, M., Tyrer, J.P., Winham, S.J., Lin, H.-Y., Chornokur, G., Dennis, J.,... Phelan, C.M. (2018). Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 13(7). https://dx.doi.org/10.1371/journal.pone.0197561
Shimelis, H., Mesman, R.L.S., Von Nicolai, C., Ehlen, A., Guidugli, L., Martin, C.,... Couch, F.J. (2017). BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 77(11), 2789-2799. https://dx.doi.org/10.1158/0008-5472.CAN-16-2568
Minlikeeva, A.N., Freudenheim, J.L., Eng, K.H., Cannioto, R.A., Friel, G., Szender, J.B.,... Moysich, K.B. (2017). History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers & Prevention, 26(9), 1470-1473. https://dx.doi.org/10.1158/1055-9965.EPI-17-0367
Brouckaert, O., Rudolph, A., Laenen, A., Keeman, R., Bolla, M.K., Wang, Q.,... Neven, P. (2017). Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. Breast Cancer Research, 19(1). https://dx.doi.org/10.1186/s13058-017-0909-3
Wyszynski, A., Hong, C.-C., Lam, K., Michailidou, K., Lytle, C., Yao, S.,... Cole, M.D. (2016). An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 25(17), 3863-3876. https://dx.doi.org/10.1093/hmg/ddw223
Hampras, S.S., Sucheston-Campbell, L.E., Cannioto, R., Chang-Claude, J., Modugno, F., Doerk, T.,... Moysich, K.B. (2016). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. https://dx.doi.org/10.18632/oncotarget.10215
Ghoussaini, M., French, J.D., Michailidou, K., Nord, S., Beesley, J., Canisus, S.,... Edwards, S.L. (2016). Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 99(4), 903-911. https://dx.doi.org/10.1016/j.ajhg.2016.07.017
Horne, H.N., Chung, C.C., Zhang, H., Yu, K., Prokunina-Olsson, L., Michailidou, K.,... Figueroa, J.D. (2016). Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 11(8). https://dx.doi.org/10.1371/journal.pone.0160316
Shi, J., Zhang, Y., Zheng, W., Michailidou, K., Ghoussaini, M., Bolla, M.K.,... Long, J. (2016). Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. International Journal of Cancer, 139(6), 1303-1317. https://dx.doi.org/10.1002/ijc.30150
Darabi, H., Beesley, J., Droit, A., Kar, S., Nord, S., Marjaneh, M.M.,... Dunning, A.M. (2016). Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). Scientific Reports, 6. https://dx.doi.org/10.1038/srep32512
French, J.D., Johnatty, S.E., Lu, Y., Beesley, J., Gao, B., Kalimutho, M.,... Macgregor, S. (2016). Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 7(6), 6353-68. https://dx.doi.org/10.18632/oncotarget.7047
Easton, D.F., Lesueur, F., Decker, B., Michailidou, K., Li, J., Allen, J.,... Chenevix-Trench, G. (2016). No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. Journal of Medical Genetics, 53(5), 298-309. https://dx.doi.org/10.1136/jmedgenet-2015-103529
Liu, J., Loncar, I., Collee, J.M., Bolla, M.K., Dennis, J., Michailidou, K.,... Hollestelle, A. (2016). rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. Scientific Reports, 6. https://dx.doi.org/10.1038/srep36874
Lei, J., Rudolph, A., Moysich, K.B., Rafiq, S., Behrens, S., Goode, E.L.,... Chang-Claude, J. (2015). Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. Breast Cancer Research, 17, 18. https://dx.doi.org/10.1186/s13058-015-0522-2
Lawrenson, K., Li, Q., Kar, S., Seo, J.-H., Tyrer, J., Spindler, T.J.,... Defazio, A. (2015). Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 6, 8234. https://dx.doi.org/10.1038/ncomms9234
Lawrenson, K., Iversen, E.S., Tyrer, J., Weber, R.P., Concannon, P., Hazelett, D.J.,... Schildkraut, J.M. (2015). Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 36(11), 1341-53. https://dx.doi.org/10.1093/carcin/bgv138
Amankwah, E.K., Lin, H.-Y., Tyrer, J.P., Lawrenson, K., Dennis, J., Chornokur, G.,... Phelan, C.M. (2015). Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 39(8), 689-97. https://dx.doi.org/10.1002/gepi.21921

Zuletzt aktualisiert 2017-27-01 um 11:42